动物造模 z-bio 2021-07-26 473

　　Objective: To use patient-derived clear cell renal cell carcinoma (ccRCC) cells (patient-derived cells, PDC) to detect the sensitivity of ccRCCPDC to molecularly targeted drugs for clinical diagnosis and treatment and experimental evidence.

　　Methods: ccRCCPDC was inoculated subcutaneously in nude mice, and the molecular target drugs sunitinib, sorafenib, lenvatinib, regorafenib, and apati were administered orally. Ni, Anlotinib. The inhibitory effect of the drug on the subcutaneous tumorigenesis of ccRCCPDC in nude mice. Collect cell and tumor tissue samples, use quantitative PCR technology to detect molecular targeted drug targets (VEGFR and other receptor tyrosine protein kinases and other protein kinases belonging to the ERK, AKT, and MAPK signaling pathways) to determine the genetic background of ccRCCPDC During the experiment. Is it stable?

　　Result: We successfully obtained 5 strains of ccRCCPDC, inoculated the above-mentioned ccRCCPDC into nude mice, and obtained a nude mouse subcutaneous tumor model of kidney cancer. In the process of culturing PDC cells in vitro, molecular targeted drug targets are reduced or lost, but due to nude mouse tumor formation, PDC cells proliferate, and the expression of molecular targeted drug targets in tumor tissues is relatively stable. Molecular targeted drugs have a relatively stable effect on the skin. The inhibitory effect of ccRCCPDC nude mice has obvious individual differences in the source of tumors in nude mice. Among the selected targeted drugs, lenvatinib has stronger anti-tumor activity than some other targeted drugs.

　　Conclusion: This study can use patient-derived renal clear cell carcinoma cell lines to establish a kidney cancer animal model, which provides theoretical and experimental basis for related clinical diagnosis and treatment. Drug cells.